-- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET --
NEWTON,
Mass., Oct. 31, 2024 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced it will
report third quarter 2024 financial results on Tuesday, November 5, 2024. Karyopharm's
management team will host a conference call and audio webcast at
8:00 a.m. ET on Tuesday, November 5,
2024, to discuss the financial results and other company
updates.
To access the conference call, please dial (800) 836-8184
(local) or (646) 357-8785 (international) at least 10 minutes prior
to the start time and ask to be joined into the Karyopharm
Therapeutics call. A live audio webcast of the call, along with
accompanying slides, will be available under "Events &
Presentations" in the Investor section of the Company's website,
http://investors.karyopharm.com/events-presentations. An archived
webcast will be available on the Company's website approximately
two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a
commercial-stage pharmaceutical company whose dedication to
pioneering novel cancer therapies is fueled by a belief in the
extraordinary strength and courage of patients with cancer. Since
its founding, Karyopharm has been an industry leader in oral
compounds that address nuclear export dysregulation, a fundamental
mechanism of oncogenesis. Karyopharm's lead compound and
firstinclass, oral exportin 1 (XPO1) inhibitor,
XPOVIO® (selinexor), is approved in the U.S. and
marketed by the Company in three oncology indications. It has also
received regulatory approvals in various indications in a growing
number of exU.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has a focused
pipeline targeting indications in multiple high unmet need cancers,
including in multiple myeloma, endometrial cancer, myelofibrosis,
and diffuse large B-cell lymphoma (DLBCL). For more information
about our people, science and pipeline, please visit
www.karyopharm.com, and follow us on LinkedIn and on X at
@Karyopharm.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc. Any other trademarks
referred to in this release are the property of their respective
owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-to-report-third-quarter-2024-financial-results-on-november-5-2024-302292411.html
SOURCE Karyopharm Therapeutics Inc.